# Animal Model Market

> Animal Model Market Research Report Information By Animal Type (Pigs, Cats, and Mice), By Technology (CRISPR, Microinjection, and Embryonic Stem Cell Injection), By Application (Research & Development, Production, and Quality Control), By End-User (Research Institutes, Educational Institutes, Pharmaceutical Companies, and Contract Research Organizations), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 7.12%
- **2024:** $ 2,777.94 Million
- **2025:** $ 2,975.74 Million
- **2035:** $ 5,919.84 Million
- **Key Players:** Companies such as Charles River Laboratories (US), Envigo (US), Taconic Biosciences (US), Harlan Laboratories (US), Crown Bioscience (US), Janvier Labs (FR), The Jackson Laboratory (US), Wuxi AppTec (CN), Inotiv (US) are some of the major participants in the global market.

**Report ID:** MRFR/Pharma/8231-HCR · **Pages:** 140 · **Author:** Rahul Gotadki · **Last Updated:** July 09, 2026

**URL:** https://www.marketresearchfuture.com/reports/animal-model-market-9709

---

## Market Summary

Global Animal Model Market Size was valued at USD 2,777.94 Million in 2024 & the market is projected to grow from USD 2,975.74 Million in 2025 to USD 5,919.84 Million by 2035, registering a CAGR of 7.12% during the forecast period 2025–2035. North America led the market with over 50% share, generating around USD 1,390.0 Million in revenue.
 
Growing investment in biopharmaceutical research and drug discovery is accelerating demand for advanced animal models that improve preclinical testing accuracy. Genetically engineered models enhance disease understanding, therapeutic validation, and regulatory success, supporting faster development of innovative medicines across multiple therapeutic areas.
 
According to the WHO Data Portal, noncommunicable diseases account for approximately 74% of global deaths annually, driving sustained investment in biomedical research where advanced animal models remain essential for preclinical evaluation of novel therapeutics and disease mechanisms.

## Market Drivers

### Emerging Markets and Globalization

Emerging markets are increasingly contributing to the Global Animal Model Market Industry as globalization facilitates collaboration and knowledge exchange. Countries in Asia-Pacific and Latin America are witnessing a rise in research activities, driven by both local and international investments.
 
This trend is fostering the development of regional animal model facilities and research institutions, which are essential for advancing scientific knowledge. The expansion of these markets is expected to enhance the overall growth of the industry, as they adopt advanced animal models for research purposes. The globalization of research initiatives is likely to create new opportunities for market players.

- According to the World Bank, middle-income economies continue increasing investments in healthcare infrastructure and biomedical research, creating favorable conditions for expanding preclinical research facilities and accelerating adoption of advanced animal models across emerging pharmaceutical markets.

### Advancements in Genetic Engineering

Advancements in genetic engineering techniques, such as CRISPR and gene editing, are significantly influencing the Global Animal Model Market Industry. These technologies enable the creation of more precise and relevant animal models that closely mimic human diseases. This precision enhances the predictability of drug responses, thereby improving the efficiency of preclinical trials.
 
As a result, researchers are increasingly adopting these advanced models, which are expected to drive market growth. The integration of genetically modified organisms into research protocols is likely to contribute to the overall expansion of the market, aligning with the projected growth trajectory leading to 2035.

- According to PubMed, CRISPR-based genome editing has significantly improved the generation of disease-specific animal models, enabling more accurate evaluation of therapeutic efficacy and accelerating translational biomedical research across multiple disease indications.

### Rising Demand for Biopharmaceuticals

The increasing demand for biopharmaceuticals is a primary driver of the Global Animal Model Market Industry. As the biopharmaceutical sector expands, the need for effective preclinical testing using animal models becomes crucial. In 2024, the market is valued at approximately 2.79 USD Billion, reflecting the industry's reliance on animal models for drug development and safety assessments.
 
This trend is expected to continue, with projections indicating a market growth to 5.93 USD Billion by 2035. The compound annual growth rate (CAGR) of 7.11% from 2025 to 2035 underscores the importance of animal models in facilitating the development of innovative therapies.

- According to IHME, the growing global burden of chronic diseases continues driving demand for innovative biologics and targeted therapies, increasing reliance on advanced animal models during preclinical safety and efficacy evaluation.

### Regulatory Support for Animal Research

Regulatory support for animal research plays a pivotal role in the Global Animal Model Market Industry. Governments and regulatory bodies are increasingly recognizing the necessity of animal models in the drug development process. This support manifests through guidelines that promote ethical research practices while ensuring the welfare of animals used in studies.
 
Such frameworks facilitate the approval of new drugs and therapies, thereby fostering innovation. As the market evolves, the alignment of regulatory policies with scientific advancements is likely to enhance the credibility and acceptance of animal models, further driving market growth through 2035.

- According to PubMed, internationally harmonized animal research guidelines have strengthened study reproducibility, ethical compliance, and regulatory acceptance, supporting broader utilization of validated animal models during pharmaceutical development.

### Increasing Investment in Research and Development

The surge in investment in research and development (R&D) across various sectors is a significant driver of the Global Animal Model Market Industry. Pharmaceutical and biotechnology companies are allocating substantial resources to R&D to discover new therapies and treatments.
 
This trend is reflected in the growing number of preclinical studies utilizing animal models, which are essential for understanding disease mechanisms and testing drug efficacy. The anticipated growth of the market from 2.79 USD Billion in 2024 to 5.93 USD Billion by 2035 highlights the critical role of R&D investments in shaping the future landscape of animal model applications.

- According to the World Bank, global expenditure on research and development has steadily increased as a percentage of GDP in many economies, supporting expansion of biomedical research programs and greater utilization of advanced animal models during preclinical development.

## Future Outlook

The Animal Model Market size is projected to reach USD 5.919 Billion by 2035, growing at a CAGR of 7.12%, driven by advancements in biotechnology, increasing R&D investments, and regulatory support.

**New opportunities:**

- Development of genetically modified animal models for precision medicine Expansion of contract research organizations offering animal model services Integration of AI technologies for enhanced data analysis in animal studies

By 2035, the Animal Model Market is expected to be robust, driven by innovation and strategic partnerships.

## Segment Insights

### By Application: Drug Discovery (Largest) vs. Toxicology Testing (Fastest-Growing)

The Animal Model Market is segmented into five primary applications: Drug Discovery, Toxicology Testing, Genetic Research, Disease Modeling, and Regenerative Medicine. Among these, Drug Discovery leads the market, accounting for a 52% share, driven by the ongoing demand for novel therapeutics and the increasing need for preclinical testing in drug development. Toxicology Testing follows closely, highlighting its importance in assessing drug safety and efficacy before human trials, capturing a significant portion of the market due to increasing regulatory requirements.

Charles River Laboratories continues expanding drug discovery capabilities through innovative preclinical platforms and strategic collaborations with global pharmaceutical companies, supporting faster identification and validation of promising therapeutic candidates across multiple disease areas.

### By Type of Animal Model: Mice (Largest) vs. Non-Human Primates (Fastest-Growing)

The Animal Model Market is largely dominated by mice, which hold a significant 60% share, owing to their cost-effectiveness and high genetic similarity to humans. Following Mice, Rats and Non-Human Primates contribute notable portions of market share, focusing on specific research areas such as neurobiology and drug development. Zebrafish and Guinea Pigs hold smaller shares, often being preferred for specialized studies and breeding practices.

Envigo continues strengthening its research model portfolio through expanded breeding capabilities and regulated laboratory animal production, supplying genetically defined mouse models that support consistent and reproducible biomedical research worldwide.

### By Research Area: Oncology (Largest) vs. Neurology (Fastest-Growing)

The Animal Model Market exhibits a complex landscape with varied shares across distinct research areas. Oncology leads the market with a 55% share, driven by its critical role in drug development and testing, along with substantial investments in cancer research. Following closely, neurology is emerging as a significant sector due to increasing research initiatives targeted towards neurodegenerative diseases, driving its market share to expand rapidly. As the industry adapts to evolving healthcare needs, other areas like cardiology, immunology, and metabolic disorders also contribute to a diversified market share across the segment values.

Oncology (Dominant) vs. Neurology (Emerging)

Oncology remains the dominant research area in the market, driven by an increasing demand for effective cancer therapies and the sophisticated models that aid in understanding tumor biology. Researchers utilize various animal models to evaluate the efficacy and safety of new oncology drugs, which fosters innovation. In contrast, neurology, while currently in an emerging phase, is gaining traction due to heightened awareness of mental health issues and neurodegenerative conditions. This shift has encouraged investments in animal models that can accurately replicate neurological diseases, accelerating drug discovery and therapeutic interventions.

### By End User: Pharmaceutical Companies (Largest) vs. Biotechnology Firms (Fastest-Growing)

The Animal Model Market features a diverse end-user base, with pharmaceutical companies accounting for the largest 62% share. This segment benefits from the increasing need for drug development and testing in preclinical phases, driving substantial demand for animal models. Following closely are biotechnology firms, which are rapidly gaining traction as they leverage innovative techniques in drug discovery and therapeutic development. In recent years, biotechnology firms have emerged as the fastest-growing segment within the Animal Model Market. This growth is propelled by the rising investment in biopharmaceuticals and increased collaborations with academic institutions and contract research organizations. As advancements in genomics and personalized medicine continue to evolve, the reliance on animal models for validation and research purposes is expected to surge, contributing to further market growth across all end-user segments.

Pharmaceutical Companies (Dominant) vs. Contract Research Organizations (Emerging)

Pharmaceutical companies serve as the dominant players in the market, leveraging extensive resources for research and development purposes. They rely heavily on animal models for preclinical testing, allowing them to assess the efficacy and safety of new drugs before human trials. This demographic is deeply invested in advancing therapeutic options and demonstrates strong demand for a variety of animal models to support their diverse research needs. In contrast, contract research organizations (CROs) are emerging as pivotal partners, providing specialized expertise and services for pharmaceutical and biotechnology companies. Their ability to offer flexible solutions and keep pace with regulatory demands positions them as important contributors to the market’s growth, enhancing preclinical research capabilities and accelerating the drug development process.

## Regional Market Share Analysis

### **North America : Market Leader in Animal Models**

North America leads in the Animal Model Market size, accounting for over 50.04% of the global revenue in 2024. The region's growth is driven by robust R&D activities, increasing investments in biotechnology, and a strong regulatory framework that supports animal research. The demand for innovative therapies and personalized medicine is also propelling market expansion, with a focus on ethical standards in animal testing.

- According to the CDC, 6 out of every 10 known infectious diseases in people originate from animals, highlighting the continued importance of advanced animal models for infectious disease research, vaccine development, and therapeutic innovation across North America.

The United States is the primary contributor, hosting key players like Charles River Laboratories and Envigo. The competitive landscape is characterized by a mix of established firms and emerging biotech companies, all vying for market share. The presence of advanced research institutions further enhances the region's capabilities, ensuring a steady supply of high-quality animal models for various research applications.

- GE HealthCare invests approximately USD 1 billion annually in research and development, supporting advanced imaging technologies and biomedical research infrastructure that strengthen preclinical animal research capabilities throughout North America.

### **Europe : Growing Hub for Research**

Europe Animal Model Market size was valued at USD 800 Million in 2024, making it the second-largest regional market with a 28.80% share. The region benefits from stringent regulations that ensure ethical treatment of animals, fostering public trust and encouraging investment in animal research. The increasing prevalence of chronic diseases and the need for effective treatments are key drivers of market growth, alongside advancements in genetic engineering and biotechnology.

- The European Medicines Agency coordinates scientific evaluation of medicines across the 27 European Union member states, supporting harmonized regulatory standards that facilitate ethical preclinical research and development of innovative therapeutics using validated animal models.

Leading countries such as Germany, France, and the UK are at the forefront, with a strong presence of companies like Janvier Labs and Harlan Laboratories. The competitive landscape is marked by collaborations between academic institutions and industry players, enhancing innovation. The European Union's commitment to animal welfare and research integrity further solidifies the region's position in the global market.

### **Asia-Pacific : Rapidly Growing Research Hub**

The Asia-Pacific region, with a market size of 470.0M, is rapidly emerging as a key player in the Animal Model Market. The asia pacific market is expanding rapidly due to increasing healthcare investments and biotechnology research advancements. Growth in China and Japan is strengthening the regional market share position globally. Countries like China and Japan are leading this trend, supported by government initiatives aimed at enhancing research infrastructure and capabilities in life sciences.

China is particularly noteworthy, with a burgeoning biotech sector and a growing number of research institutions. The competitive landscape features both local and international players, including Wuxi AppTec, which is expanding its footprint in the region. As the demand for animal models continues to rise, Asia-Pacific is set to play a crucial role in global research and development efforts, focusing on both quality and ethical standards.

### **Middle East and Africa : Emerging Market with Unique Challenges**

The Middle East and Africa region, valued at 117.94M, presents unique challenges and opportunities in the Animal Model Market. The MEA region contributes gradually to the global market, supported by healthcare infrastructure improvements and rising research initiatives within the animal model services market. Countries like South Africa and the UAE are making strides in establishing research facilities and fostering collaborations to enhance their capabilities in animal model research.

South Africa is leading the way, with a focus on improving research standards and ethical practices. The competitive landscape is still developing, with a mix of local and international players. As the region continues to invest in research and development, it is expected to gradually overcome existing challenges, paving the way for a more robust market.

## Competitive Benchmarking

The Animal Model Market is characterized by a dynamic competitive landscape, driven by increasing demand for innovative research methodologies and the growing prevalence of chronic diseases. Key players such as Charles River Laboratories (US), Envigo (US), and The Jackson Laboratory (US) are strategically positioned to leverage their extensive portfolios and operational capabilities.
 
Charles River Laboratories (US) focuses on enhancing its service offerings through technological advancements and strategic partnerships, which appear to bolster its market presence. Similarly, Envigo (US) emphasizes sustainability and ethical practices in animal research, aligning its operations with evolving regulatory standards and consumer expectations.
 
The collective strategies of these companies contribute to a moderately fragmented market structure, where innovation and compliance are pivotal for competitive advantage.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness. The competitive structure of the market remains moderately fragmented, with several players vying for market share.
 
This fragmentation is indicative of a landscape where smaller firms can thrive alongside larger entities, driven by niche offerings and specialized services. The influence of key players is substantial, as they set benchmarks for quality and innovation, thereby shaping market dynamics.

In November Charles River Laboratories (US) announced a strategic partnership with a leading biotechnology firm to develop advanced gene-editing models. This collaboration is poised to enhance their research capabilities, allowing for more precise and effective drug development processes. The strategic importance of this partnership lies in its potential to position Charles River as a frontrunner in the rapidly evolving field of genetic research, thereby attracting more clients seeking cutting-edge solutions.
 
In October Envigo (US) launched a new line of environmentally sustainable animal models, which reflects its commitment to ethical research practices. This initiative not only addresses growing consumer concerns regarding animal welfare but also aligns with global sustainability trends. The introduction of these models is likely to enhance Envigo's competitive edge, appealing to organizations that prioritize ethical considerations in their research methodologies.
 
In September The Jackson Laboratory (US) expanded its global footprint by establishing a new facility in Asia, aimed at catering to the increasing demand for animal models in the region. This expansion is strategically significant as it allows The Jackson Laboratory to tap into emerging markets, thereby diversifying its revenue streams and enhancing its operational capabilities. The move underscores the importance of geographical diversification in maintaining competitiveness in a globalized market.

As of December current trends in the Animal Model Market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) in research processes. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in driving innovation and enhancing operational efficiencies.
 
Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on technological advancements, innovative solutions, and reliable supply chains. This shift suggests that companies that prioritize research and development, alongside sustainable practices, will be better positioned to thrive in the future.

## Recent News & Developments

- **Q2 2024: Charles River Laboratories Announces Opening of New Preclinical Research Facility in North Carolina** Charles River Laboratories opened a new state-of-the-art preclinical research facility in North Carolina to expand its capacity for animal model-based drug development and testing.
- **Q1 2024: GenOway and Merck KGaA Announce Strategic Partnership to Develop Next-Generation Humanized Mouse Models** GenOway entered a strategic partnership with Merck KGaA to co-develop advanced humanized mouse models for immuno-oncology and autoimmune disease research.
- **Q2 2024: Taconic Biosciences Launches New CRISPR-Engineered Rat Model for Neurological Disease Research** Taconic Biosciences launched a new CRISPR-engineered rat model designed to accelerate preclinical studies in neurological disorders.
- **Q3 2024: Eurofins Scientific Expands market Services with Acquisition of Preclinical CRO in Japan** Eurofins Scientific acquired a leading Japanese preclinical contract research organization to strengthen its animal model services and global reach.
- **Q2 2024: The Jackson Laboratory Receives NIH Grant to Develop Rare Disease Mouse Models** The Jackson Laboratory was awarded a multi-million dollar NIH grant to develop and distribute new mouse models for rare genetic diseases.
- **Q1 2025: Envigo Appoints New CEO to Lead Global Expansion in market Research** Envigo announced the appointment of a new CEO to drive its global expansion and innovation in animal model research services.
- **Q2 2025: Charles River Laboratories Acquires Hera BioLabs to Expand Portfolio of Gene-Edited Animal Models** Charles River Laboratories acquired Hera BioLabs, enhancing its portfolio of gene-edited animal models for drug discovery and safety testing.
- **Q1 2024: Biocytogen Raises $60 Million in Series C Funding to Accelerate Development of Humanized Animal Models** Biocytogen secured $60 million in Series C funding to expand its pipeline of humanized animal models for pharmaceutical research.
- **Q3 2024: JSR Corporation Announces Strategic Investment in Ozgene to Advance Genetically Modified market Technologies** JSR Corporation made a strategic investment in Ozgene to support the development of next-generation genetically modified animal models.
- **Q2 2025: PerkinElmer Launches New Zebrafish Model Platform for High-Throughput Drug Screening** PerkinElmer introduced a new zebrafish model platform aimed at enabling high-throughput drug screening for early-stage pharmaceutical research.
- **Q1 2025: Trans Genic Inc. Wins Major Contract to Supply Custom Animal Models for European Biotech Consortium** Trans Genic Inc. secured a significant contract to supply custom animal models to a consortium of European biotech firms for collaborative research projects.
- **Q2 2024: Envigo Opens New market Production Facility in Germany** Envigo opened a new production facility in Germany to meet growing demand for specialized animal models in European biomedical research.

## Report Scope

| MARKET SIZE 2024 | 2777.94(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 2975.74(USD Million) |
| MARKET SIZE 2035 | 5919.84(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.12% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Charles River Laboratories (US), Envigo (US), Taconic Biosciences (US), Harlan Laboratories (US), Crown Bioscience (US), Janvier Labs (FR), The Jackson Laboratory (US), Laboratory Animal Resources (US) |
| Segments Covered | Application, Type of Animal Model, End User |
| Key Market Opportunities | Advancements in genetic engineering enhance precision in the market for drug development. |
| Key Market Dynamics | Rising demand for advanced therapies drives innovation and competition in the market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the current valuation of the Animal Model Market as of 2024?**
A: The market was valued at 2777.94 USD Million in 2024.

**Q: What is the projected market size for the market by 2035?**
A: The market is projected to reach 5919.84 USD Million by 2035.

**Q: What is the expected CAGR for the Animal Model Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the market during the forecast period 2025 - 2035 is 7.12%.

**Q: Which application segments are driving growth in the Animal Model Market?**
A: Key application segments include Drug Discovery, Toxicology Testing, and Regenerative Medicine, with valuations ranging from 600.0 to 1519.84 USD Million.

**Q: What types of animal models are most commonly used in research?**
A: Mice and rats are the most commonly used animal models, with market valuations between 500.0 and 1300.0 USD Million.

**Q: Which research areas are seeing the highest investment in the Animal Model Market?**
A: Oncology and Neurology are leading research areas, with market valuations reaching up to 1300.0 USD Million.

**Q: Who are the key players in the market?**
A: Key players include Charles River Laboratories, Envigo, and The Jackson Laboratory, among others.

**Q: What are the primary end users of animal models in research?**
A: Pharmaceutical companies and biotechnology firms are the primary end users, with market valuations between 555.09 and 2390.0 USD Million.

**Q: How does the market for non-human primates compare to other animal types?**
A: The market for non-human primates is valued between 400.0 and 800.0 USD Million, which is lower than that of mice and rats.

**Q: What trends are influencing the growth of the Animal Model Market?**
A: Trends such as advancements in genetic research and increasing demand for regenerative medicine are likely influencing market growth.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/animal-model-market-9709*